Second quarter 2021 (1 April – 30 June):

Net revenue was KDKK 0 Operating result was KDKK -3,088 Net result was KDKK -2,641Cash at bank end of the period was KDKK 9,465 Earnings per share* was KDKK -0,72Solidity** was 88%

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 June 2021 amounted to 3,680,000 shares, the average number of shares during the second quarter was 3,680,000. There has been an increase in the number of shares since the completion of the IPO in December 2020.

 **Solidity: Total equity divided by total capital and liability.

Highlights during second quarter 2021

Completed recruitment for trial 0204, final results expected end of the yearReady to initiate recruitment for trial 0206Preparing for the pivotal trial 0205Initiated formulation activities of CT002Awarded IPO of the year by Affärsvälden Continue to build the organization to lead the development of CT001Appointed Adam Steensberg as Chairman of the Board

“The second quarter of 2021 has focused much on clinical activities, with coordinating and executing three (3) clinical trials in parallel - in particular preparing for the pivotal trial 0205 with more than 220 patients has been a major effort, more will continue in Q3 and Q4. The Company was awarded IPO of the year by Affärsvälden, which was another recognition of our hard work and we are proud to have initiated early formulation activities for our second product candidate CT002 - the outlook is really positive for the Company and it looks like 2021 will be a promising year” says Jes Trygved, CEO